Loading data for ACRV — first visit, this takes a few seconds.

アラート

Acrivon Therapeutics Inc. (ACRV)

NasdaqGM: ACRV · リアルタイム株価 · USD

2.23

+0.03 (1.36%)

終値時点： Aug 21, 2026, 8:00 PM

2.21

+0.00%

時間外: 4:10 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

1.36% (1D)

データがありません

買気配	1.14
時価総額	94.71M
売上高（TTM）	n/a
純利益（TTM）	-74.22M
	1.86
	-1.88
	n/a
	-1.28
PBR（TTM）	1.09
PSR（TTM）	n/a
決算発表日	Aug 14, 2025

売気配	2.06
出来高	294,614
平均出来高（20日）	422,112
始値	2.21
前日終値	2.20
当日レンジ	2.18 - 2.31
52週レンジ	1.27 - 3.56
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

ACRVについて

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are ...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Nov 15, 2022

従業員数 74

上場取引所 NasdaqGM

ティッカー ACRV

ウェブサイト https://acrivon.com

企業情報の全文

業績

2025年のAcrivon Therapeuticsの売上高は0で、前年の0からundefined%の増加でした。利益は-77.91Mで、-3.29%の減少でした。

財務諸表

決算サプライズ

Acrivon TherapeuticsはAug 12, 2026に四半期決算を発表しました：

売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.

EPSは -0.43 で、予想を上回りました 0.07, うち 21.82% の前年比増加にあたります.

次回決算発表

Acrivon Therapeutics Inc.の決算発表予定日は Aug 14, 2025, 引け後の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

5か月前 · Zacks

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why

Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

5か月前 · MarketBeat

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer

Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company’s ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer, with...

7か月前 · Simply Wall St.

Penny Stocks To Watch In January 2026

As the U.S. markets grapple with recent declines and rising Treasury yields, investors are keenly observing potential opportunities in various sectors. Penny stocks, while often seen as relics of past...

7か月前 · Simply Wall St.

Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares

Even if it's not a huge purchase, we think it was good to see that Peter Blume-Jensen, the Co-Founder of Acrivon...

7か月前 · Zacks

Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?

Here is how Humacyte, Inc. (HUMA) and Acrivon Therapeutics, Inc. (ACRV) have performed compared to their sector so far this year.

2ページ中1ページ

Acrivon Therapeutics Inc. (ACRV)